The analysis by US biotech Circular Genomics focuses on an assay that looks for a circular RNA (circRNA) blood biomarker that ...
Before donanemab takes the stand, on 4th June another group of FDA advisors will also cast their eye over Lykos Therapeutics’ ...
Levin, MSc, is President of Medical Communications across Area23 on Hudson, ProHealth, and Trio, as well as the Commercial Medical Communications Champion at IPG Health Network. A twenty-year industry ...
Our round-up of recent biotech financings is headed by a sizeable $200 million third round for Zenas BioPharma, with Cellectis, Reunion Neuroscience, Karius, Context Therapeutics, and Enlaza also ...
A new study has shown that a generative AI (GenAI) tool developed by life sciences AI specialist Sorcero, built on Google ...
The Novo Nordisk Foundation, the Bill & Melinda Gates Foundation, and Wellcome have joined forces to tackle some of the most ...
Boehringer Ingelheim says it may have found the first therapy for diabetic macular ischaemia (DMI), a common and irreversible ...
Alpibectir was developed in a public-private collaboration between GSK, Pasteur Institute Lille, and the University of Lille, and is designed as a companion to ethionamide (Eto), which is an important ...
Late last month, pharmaphorum was invited on an IDA Ireland-organised press tour of the life sciences industry in Ireland’s West, permitting an inside peek into the world-class life sciences ...
Two-year data with eyeDNA Therapeutics’ gene therapy for retinitis pigmentosa (RP), an inherited form of blindness, has prompted the biotech to seek discussions with regulators about the design of a ...
For more than 15 years, shortages of critical drugs — from oncology treatments to emergency room and surgical suite essentials — have burdened healthcare systems and compromised patient care and ...
Two-year data with eyeDNA Therapeutics’ gene therapy for retinitis pigmentosa (RP), an inherited form of blindness, has prompted the biotech to seek discussions with regulators about the design of a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results